The direct profibrotic and indirect immune antifibrotic balance of blocking the cannabinoid 2 receptor

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 302, Issue 12, 2012, Pages

  Avraham, Yosefa ^a   Amer, Johnny ^b   Doron, Sarit ^b   Abu Tair, Lina ^b   Mahamid, Mahmud ^b,c   Khatib, Areej ^d   Berry, Elliot M ^a   Safadi, Rifaat ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c Israel   (Israel)

^d Bethlehem University   (Israel)

Author keywords

Hepatic stellate cells; Liver injury; Lymphocytes

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; CANNABINOID 2 RECEPTOR; CARBON TETRACHLORIDE; CD4 ANTIGEN; CD8 ANTIGEN;

ADOPTIVE TRANSFER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNITY; IN VITRO STUDY; LIVER FIBROSIS; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RAT; SPLEEN CELL; STELLATE CELL;

EID: 84862540923     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00191.2011     Document Type: Article

References (32)

1. Basu SB, Dittel N. Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunol Res 51: 2638, 2011.
2. Bouaboula M, Rinaldi M, Carayon P, Carayon P, Carillon C, Delpech B, Shire D, Le Fur G, Casellas P. Cannabinoid-receptor expression in human leukocytes. Eur J Biochem 214: 173-180, 1993.
3. Cota D, Marsicano G, Tschöp M, Grübler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thöne-Reineke C, Ortmann S, To-massoni F, Cervino C, Nisoli E, Linthorst AC, Pasquali R, Lutz B, Stalla GK, Pagotto U. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112: 423-431, 2003.
4. Croci T, Aureggi G, Guagnini F, Manara L, Gully D, Fur GL, Maffrand JP, Mukenge S, Ferla G, Ferrara P, Chalon P, Vita N. In vitro functional evidence of neuronal cannabinoid CB1 receptors in human. Br J Pharmacol 127: 1922-1928, 1999.
5. Ziring D, Wei B, Velazquez P, Schrage M, Buckley EN, Braun J. Formation of B and T cell subsets require the cannabinoid receptor CB2. Immunogenetics 58: 714-725, 2006.
6. Deveaux V, Cadoudal T, Ichigotani Y, Teixeira-Clerc F, Louvet A, Manin S, Nhieu JT, Belot MP, Zimmer A, Even P, Cani PD, Knauf C, Burcelin R, Bertola A, Le Marchand-Brustel Y, Gual P, Mallat A, Lotersztajn S. Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS ONE 4: e5844, 2009.
7. Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 21: 311-335, 2001.
8. Geerts A, Eliasson C, Niki T, Wielant F, Pekny M. Formation of normal desmin intermediate filaments in mouse hepatic stellate cells requires vimentin. Hepatology 33: 177-188, 2001.
9. Julien B, Grenard P, Teixeira-Clerc F, Van Nhieu JT, Li L, Karsak M, Zimmer A, Mallat A, Lotersztajn S. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 128: 742-755, 2005.
10. Liu J, Gao B, Mirshahi F, Sanyal AJ, Khanolkar AD, Makriyannis A, Kunos G. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 346: 835-840, 2000.
11. Magen I, Avraham Y, Berry E, Mechoulam R. Endocannabinoids in liver disease and hepatic encephalopathy. Curr Pharm Des 14: 2362-2369, 2008.
12. Mallat A, Lotersztajn S. Cannabinoid receptors as therapeutic targets in the management of liver diseases. Drug News Perspect 21: 363-368, 2008.
13. Melhem A, Muhanna N, Bishara A, Alvarez CE, Ilan Y, Bishara T, Horani A, Nassar M, Friedman SL, Safadi R. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol 45: 60-71, 2006.
14. Miranda SR, Erlich S, Visser JW, Gatt S, Dagan A, Friedrich VL, Schuchman EH. Bone marrow transplantation in acid sphingomyelinase-deficient mice: engraftment and cell migration into the brain as a function of radiation, age, and phenotype. Blood 90: 444-452, 1997.
15. Muhanna N, Abu-Tair L, Doron S, Amer J, Azzeh M, Mahamid M, Friedman S, Safadi R. Amelioration of hepatic fibrosis by NK cell activation. Gut 60: 90-98, 2011.
16. Muhanna N, Horani A, Doron S, Safadi R. Lymphocyte-hepatic stellate cell proximity suggests a direct interaction. Clin Exp Immunol 148: 338-347, 2007.
17. Muhanna N, Doron S, Wald O, Horani A, Eid A, Pappo O, Friedman SL, Safadi R. Activation of hepatic stellate cells following phagocytosis of lymphocytes-a novel pathway of fibrogenesis. Hepatology 48: 963-977, 2008.
18. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65, 1993.
19. Muñoz-Luque J, Ros J, Fernández-Varo G, Tugues S, Morales-Ruiz M, Alvarez CE, Friedman SL, Arroyo V, Jiménez W. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther 324: 475-483, 2008.
20. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Bátkai S, Harvey-White J, Mackie K, Offertáler L, Wang L, Kunos G. Endo-cannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115: 1298-1305, 2005.
21. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58: 389-462, 2006.
22. Parfieniuk A, Flisiak R. Role of cannabinoids in chronic liver diseases. World J Gastroenterol 14: 6109-6114, 2008.
23. Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B, Portier M, Shire D, Brelière JC, Le Fur GL. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 284: 644-501, 1998.
24. Safadi R, Ohta M, Alvarez CE, Fiel I, Bansal M, Mehal W, Friedman SL. Immune stimulation of hepatic fibrogenesis by CD8 lymphocytes and its attenuation by transgenic interleukin from hepatocytes. Gastroenterology 127: 870-882, 2004.
25. Safadi R, Alvarez CE, Ohta M, Brimnes J, Kraus T, Mehal W, Brom-berg J, Mayer L, Friedman SL. Enhanced oral tolerance in transgenic mice with hepatocyte secretion of IL-10. J Immunol 175: 3577-3583, 2005.
26. Siegmund SV, Uchinami H, Osawa Y, Brenner DA, Schwabe RF. Anandamide induces necrosis in primary hepatic stellate cells. Hepatology 41: 1085-1095, 2005.
27. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, Karsak M, Zimmer A, Frossard JL, Mach F. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nat Med 434: 782-786, 2005.
28. Sugiura T, Kishimoto S, Oka S, Gokoh M. Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog Lipid Res 45: 405-446, 2006.
29. Teixeira-Clerc F, Belot MP, Manin S, Deveaux V, Cadoudal T, Chobert MN, Louvet A, Zimmer A, Tordjmann T, Mallat A, Lotersz-tajn S. Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration. Hepatology 52: 1046-1059, 2010.
30. Teixeira-Clerc F, Julien B, Grenard P, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 12: 671-676, 2006.
31. Van de Poorten D, Shahidi M, Tay E, Sesha J, Tran K, McLeod D, Milliken JS, Ho V, Hebbard LW, Douglas MW, George J. Hepatitis C virus induces the cannabinoid receptor 1. PLoS One 5: e1284, 12010.
32. Xu L, Hui AY, Albanis E, Arthur MJ, O'Byrne SM, Blaner WS, Mukherjee P, Friedman SL, Eng FJ. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 54: 142-115, 2005.